A bill to ban supervised injection sites in Pennsylvania passed in the Senate on Monday and has moved to the House Judiciary Committee. Pennsylvania Sen. Christine Tartaglione, D-Philadelphia, introduced the bill in December and has been outspoken about supporting such legislation for years. Gov. Josh Shapiro, who has expressed opposition to supervised injection sites, is expected to sign the legislation if it passes in the House, which reconvenes later this month.
At a supervised injection site, also called supervised consumption or safe injection, people who use drugs can do so under the watchful eye of medical professionals. A plethora of resources also exist on-site, including the opioid-reversal medication naloxone, clean needles and recovery resources.
Supervised consumption is illegal federally, but in July 2021, Rhode Island greenlit a pilot program to develop a site in Providence, and, on Nov. 30, 2021, then-New York City Mayor Bill de Blasio signed off on the opening of two sites. The model is widespread across the globe, including in Vancouver, Canada, and Geneva, Switzerland. Philadelphia nonprofit Safehouse has for years tried to become a supervised consumption site.
Senate Bill 165 passed 41 to 9 on Monday, with all Republicans and 13 Democrats in support of the ban. All nine who voted not to support the ban were Democrats.
“We are committed to finding the appropriate strategy, including adequately funding treatment and community-based recovery support services, to help curb this epidemic and dramatically decrease the amount of overdose deaths occurring in the Commonwealth,” Ms. Tartaglione wrote in the bill’s memorandum, adding that “safe injection sites are counter-productive to this overall goal.”
The bill will not affect syringe service programs throughout the state, which Allegheny County has judiciary exceptions to administer.
Alice Bell, overdose prevention project coordinator with Prevention Point Pittsburgh, said she was frustrated with the bill’s Senate passage. Prevention Point is not a supervised consumption site but administers syringe services and other harm reduction methods, such as overdose response training and Narcan distribution, in Pittsburgh and Philadelphia.
“It makes no sense to take this important option off the table,” said Ms. Bell, who has worked for decades with people who use drugs. “We know that no one has ever died of an overdose at a supervised injection site.”
Pennsylvania has one of the highest opioid overdose death rates in the country. In Allegheny County, the overdose death rate in 2021 was nearly double the U.S. rate, with an average of 477 annual deaths, primarily from the potent synthetic opioid fentanyl, per Allegheny County Health Department’s overdose dashboard.
OnPoint NYC, a nonprofit with supervised consumption locations in Manhattan’s Washington Heights and East Harlem neighborhoods, has, since opening in 2021, responded to 898 overdoses at its facilities, which have been utilized more than 70,000 times, according to preliminary data. Outside the facilities, by contrast, a fatal overdose occurs every three hours, with more than 2,650 deaths every year.
Insite, in Vancouver, has responded to 6,440 overdoses since opening in 2003, with no reported deaths.
Open about her own history, Ms. Tartaglione said in an email statement to the Post-Gazette that her experience recovering from an alcohol addiction has informed her approach to Senate legislation.
“I understand the devastating impact addiction can have on individuals, families, communities, and beyond,” she said. “My goal as a legislator is to better my community with every action I take. I will continue advocating for additional investments in addiction treatment and recovery programs to ensure all Pennsylvanians have access to quality and accessible recovery treatment.”

Supporting the ban, State Sen. Jim Brewster, D-Allegheny, said he didn’t think supervised injection sites were the solution for treating addiction.
“I don’t see the plan, I don’t see the vision, and I think it enables people,” he said. “I live in Allegheny County, and I know what we’re doing here, and it’s not enough.”
He intends to focus on the argument that addiction is a disease and set up treatment facilities around the state.
“My plan has always been to get patients into a facility and treat them,” he said. Mr. Brewster also noted he supports harsh sentences for high-level drug dealers who do not struggle with addiction.
Harm reduction experts interviewed said supervised injection sites work best to reduce overdose deaths compared to other strategies.
“What are those alternatives?” Linda Hurley, president and CEO of Codac Behavioral Health in Rhode Island, asked. “There isn’t any other truly strong harm reduction tool.”
Ms. Hurley, who has worked in the recovery space for decades, applied for a $2.25 million grant to access Rhode Island opioid settlement money to build the first state-regulated supervised consumption facility in the country: She said her team worked closely with the Rhode Island Department of Health to create regulations around the space. Their plan is to use the first floor of a new facility for supervised injection, or what many harm reduction experts prefer to call “overdose prevention centers,” with the ability to test drugs on-site, as well as an opioid treatment center on the second floor.
Peer recovery support specialists and a team consisting of a nurse, doctor, counselor and liaison would all be present at the site to support both safe consumption of drugs and detox and recovery from substances should visitors seek it. They hope to be fully operational sometime next January.
“I’m remarkably excited,” she said. “We need to keep people alive until they can reach whatever they see as recovery. When they’re tired of continued use, they’ll trust us enough to come and ask for help.”
Ms. Hurley was saddened by the news of SB165. She is from Philadelphia and said when she recently visited Kensington (largely seen as ground zero for the opioid crisis in Philly), she could see what needed to be done.
Research has revealed “really robust outcomes” about overdose prevention centers, said Dr. James Latronica, an addiction specialist physician and the public policy chair and president-elect of the Pennsylvania Society of Addiction Medicine.
Among the benefits, he said, are that they reduce the burden on EMS, transmission of blood-borne pathogens due to use of clean needles, and litter in the community, because fewer people are injecting substances on the street. And, he said, the sites do not increase the rate of any substance use or new diagnoses of substance use disorder.
“We have safe consumption sites and a safe supply for other drugs,” he said. While acknowledging that alcohol and fentanyl are not the same, he pointed to the regulated market of alcohol and said when entering a bar, patrons understand that glasses will be clean and that alcohol provided will be measured out and free of poison. “It’s a safe place to use a dangerous substance,” he said.
He called the Senate bill a “punch in the gut,” and “completely discordant to everything we know helps to reduce overdoses.”
While supervised consumption sites alone are not going to solve the complex problem of the opioid crisis, he said, what they will do is offer patients another chance to live every time they use.
“I can’t treat patients if they’re already dead,” he said. “By suggesting legislation like this, we are tacitly approving a huge number of deaths.”
Of those who voted against the ban, Sen. Lindsey Williams, D-Allegheny, declined to comment, citing the ongoing Post-Gazette labor dispute. Sens. Amanda Cappelletti, D-Montgomery, and Nikil Saval, D-Philadelphia, did not respond to requests for comment. House Judiciary Committee Chair Tim Briggs, D-Montgomery, also did not respond to a phone call.
The fate of the bill in the House is unclear. Another bill tied to a harm reduction strategy — one that legalized fentanyl test strips in Pennsylvania — originated in the House last session and was signed into law by then-Gov. Tom Wolf.
The chamber is not back in session until May 22. Regardless of what the Legislature does, Gov. Josh Shapiro made a strong statement on the issue last month when he said, “I do not support safe injection sites.”
Judith Schwank, D-Berks, voted against the ban and said it was short-sighted to rule out a harm reduction technique when opioid overdoses continue to plague communities at such a deadly rate.
“It seems to me that it’s far better to make a connection with someone than having them use [drugs] in a dirty room and potentially overdose,” Ms. Schwank said. “If we can keep people alive, maybe we can get them into treatment.”
She worries the legislation will set the state back significantly in its progress to reduce overdose deaths.
“Just like treatment, one size does not fit all in terms of how models are made available in communities. It’s really disappointing to me,” she said.
Allegheny County councilwoman Bethany Hallam tweeted on Wednesday, “Shame on every one of our state senators who voted to ban these lifesaving centers.”
The legislation, Dr. Latronica said, is “the end result of a century of militant drug policy. Usage rates have stayed roughly the same for all substances since the War on Drugs. But we see policy that flies in the face of that evidence … We are taking one of the few tools we have out of our arsenal.”
Hanna Webster: hwebster@post-gazette.com






Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.